Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-03 03:37:59 - browse：893

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： KalVista pill reduced swelling 'attacks' caused by genetic disease

WSS

American TikTok star stuck in Dubai for months following rental car altercation

What we’ve learned from the Aduhelm mess

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

Snowpack in the West is melting rapidly. Where will all that extra water go?

How digital tools helped lower hypertension in marginalized patients

House GOP plan to stem drug shortages differs from Democrats’

hotspot

Wikipedia

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: How biotech is using artificial intelligence

In Memoriam: Notable people who died in 2023

A disappointing year of Humira biosimilars

How to save PrEP access — and even expand it

The Readout: Gilead, Bernie Sanders, and other pharma news

As demand for Covid shots wanes, Moderna seeks its next success

House GOP plan to stem drug shortages differs from Democrats’

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medicare Advantage proposed rates disappoint insurers

focus

A disappointing year of Humira biosimilars

For Medicare Advantage, Democrats want stronger protections around AI

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

Biogen Alzheimer’s drug launch off to slow start

Snowpack in the West is melting rapidly. Where will all that extra water go?

Teacher posts viral 'school supply rant' with advice for parents

leisure time

focus

hotspot

Wikipedia